Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank AB

Swedbank AB raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 227,779 shares of the biopharmaceutical company's stock after buying an additional 20,409 shares during the quarter. Swedbank AB owned approximately 0.22% of Regeneron Pharmaceuticals worth $175,816,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Torren Management LLC acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $38,000. Finally, FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on REGN. TD Cowen upped their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a "buy" rating in a research note on Thursday, April 23rd. Evercore raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research report on Thursday, January 22nd. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating on the stock in a report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a research report on Monday, February 2nd. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $826.59.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares of the company's stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,874 shares of company stock worth $3,013,262. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $702.45 on Wednesday. The company has a market cap of $74.26 billion, a P/E ratio of 17.12, a PEG ratio of 1.58 and a beta of 0.30. The firm has a fifty day moving average price of $755.26 and a 200 day moving average price of $738.45. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals's revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the business earned $8.22 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.85 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.